세계 의약품 위탁개발생산 시장 규모는 2023년 1,222억 2,200만 달러로 2024년 1,306억 3,000만 달러에서 2032년 2,227억 8,000만 달러로 성장할 것으로 예상되며, 예측 기간(2025-2032년) 동안 6.9%의 CAGR을 기록할 것으로 예상됩니다.
의약품 위탁개발생산 시장은 첨단 기술 도입 확대, 특허 만료, R&D 투자 증가 등 여러 요인에 의해 강력한 성장세를 보이고 있으며, COVID-19 사태로 인한 제네릭 및 생물학적 제제에 대한 수요 증가는 이러한 성장세를 더욱 촉진하고 있습니다. 또한 세포 및 유전자 치료제, 맞춤형 의약품, 고활성 의약품 성분(HPAPI), 항체약물접합체(ADC)에 대한 수요 증가도 시장 성장을 견인하고 있습니다. 그러나 시리얼라이제이션의 도입과 전문 인력 부족은 시장 성장을 저해하는 요인으로 작용할 수 있습니다. 앞으로 기업들은 이러한 역학을 잘 활용하여 새로운 기회를 활용하고 변화하는 환경 속에서 성장을 유지하기 위해 노력해야 합니다.
Global Pharmaceutical Contract Development and Manufacturing Market size was valued at USD 122.2 billion in 2023 and is poised to grow from USD 130.63 billion in 2024 to USD 222.78 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).
The pharmaceutical contract development and manufacturing market is experiencing robust growth driven by multiple factors, including the increasing adoption of advanced technologies, patent expirations, and heightened investments in research and development. Demand for generic medications and biologics, spurred by the COVID-19 pandemic, further fuels this expansion. The market is also poised for growth due to the rising need for cell and gene therapies, customized medicines, high potency active pharmaceutical ingredients (HPAPIs), and antibody-drug conjugates (ADCs). However, challenges such as the implementation of serialization and a shortage of qualified professionals may hinder progress. Moving forward, firms must navigate these dynamics to capitalize on emerging opportunities and sustain growth in this evolving landscape.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pharmaceutical Contract Development And Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Pharmaceutical Contract Development And Manufacturing Market Segmental Analysis
Global Pharmaceutical Contract Development and Manufacturing Market is segmented by Service, End User and region. Based on Service, the market is segmented into Pharmaceutical Manufacturing Services, Drug Development Services, Biologics Manufacturing Services and Packaging Services. Based on End User, the market is segmented into Large Pharmaceutical Companies, Small and Mid-size Pharmaceutical Companies, Generic Pharmaceutical Companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Pharmaceutical Contract Development And Manufacturing Market
The Global Pharmaceutical Contract Development and Manufacturing market is experiencing significant growth due to the rising demand for pharmaceuticals targeting chronic illnesses. This demand is further bolstered by the numerous benefits of outsourcing, particularly in terms of cost and time efficiency. Companies in this sector are investing heavily in enhancing their infrastructure, workforce, and technological capabilities to capture a larger portion of the outsourcing market. This trend underscores the shift towards outsourcing as a strategic move for pharmaceutical firms looking to streamline operations and optimize resources, thus driving the overall expansion of the contract development and manufacturing landscape.
Restraints in the Global Pharmaceutical Contract Development And Manufacturing Market
The Global Pharmaceutical Contract Development and Manufacturing market faces significant restraints, particularly due to a shortage of skilled labor, which threatens to impede market growth. Inadequate understanding of production processes can lead to defective product lines, thereby eroding consumer trust. This lack of confidence poses a risk not only to the relationships among developers, manufacturers, and distributors but also to the overall integrity of the market. As a result, addressing workforce shortages and enhancing process knowledge are crucial to mitigate the potential negative impacts and ensure a reliable and effective contract development and manufacturing ecosystem in the pharmaceutical industry.
Market Trends of the Global Pharmaceutical Contract Development And Manufacturing Market
The Global Pharmaceutical Contract Development and Manufacturing market is experiencing significant growth, driven primarily by the rising incidence of cancer and advancements in technology that facilitate the development of safe and effective medications. This trend underscores a burgeoning demand for oncology treatments, leading to a heightened focus on highly potent New Chemical Entities (NCEs). As researchers and manufacturers prioritize the creation of selective compounds that optimize therapeutic efficacy while minimizing dosing frequencies, Contract Development and Manufacturing Organizations (CDMOs) are increasingly leveraged to expedite the drug development process, aligning with the industry's shift towards personalized medicine and targeted therapies.